Leeward Investments LLC MA Purchases 19,385 Shares of Globus Medical, Inc. $GMED

Posted by George Bondi on May 15th, 2026

Leeward Investments LLC MA increased its position in Globus Medical, Inc. (NYSE:GMED – Free Report) by 12.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 172,641 shares of the medical device company’s stock after purchasing an additional 19,385 shares during the quarter. Leeward Investments LLC MA owned approximately 0.13% of Globus Medical worth $15,073,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of GMED. Alliancebernstein L.P. raised its holdings in shares of Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after purchasing an additional 1,908,795 shares during the period. ANTIPODES PARTNERS Ltd raised its holdings in Globus Medical by 49,020.3% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock valued at $51,034,000 after acquiring an additional 889,229 shares during the period. Dimensional Fund Advisors LP raised its holdings in Globus Medical by 72.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company’s stock valued at $115,166,000 after acquiring an additional 842,547 shares during the period. Vestal Point Capital LP raised its holdings in Globus Medical by 150.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,250,000 shares of the medical device company’s stock valued at $71,588,000 after acquiring an additional 750,000 shares during the period. Finally, Sculptor Capital LP raised its holdings in Globus Medical by 31.9% in the 2nd quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after acquiring an additional 667,850 shares during the period. 95.16% of the stock is owned by institutional investors.

Insider Activity at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 18.38% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Truist Financial set a $115.00 price target on shares of Globus Medical in a report on Wednesday, February 25th. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Finally, Barclays increased their price target on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and an average price target of $106.36.

Get Our Latest Stock Analysis on GMED

Globus Medical Trading Up 2.2%

Shares of GMED opened at $77.25 on Friday. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40. The firm’s 50 day moving average is $88.05 and its 200-day moving average is $87.16. The stock has a market capitalization of $10.45 billion, a PE ratio of 17.96, a P/E/G ratio of 1.56 and a beta of 1.00.

Globus Medical (NYSE:GMED – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same period last year, the firm earned $0.68 earnings per share. The business’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Equities research analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Globus Medical Profile

(Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.